Company intelligence / Profile preview

AtriAN Medical

Ownership: Private
Development stage: Phase 1

Overview

AtriAN Medical has developed a novel pulsed field ablation technology targeting the autonomic drivers of atrial fibrillation by selectively ablating cardiac ganglionated plexi while sparing healthy myocardium. Two early clinical studies have been completed, demonstrating safety and feasibility of the approach as an adjunct to cardiac surgery for patients with atrial fibrillation. The company is preparing for further clinical development using minimally invasive access routes

Therapeutic areas: Cardiovascular
Modalities: Device (Pulsed Electric Field Ablation system)Non-pharmacological therapy (cardioneuroablation)
Industry: Surgical Medical Devices

Partnerships

Mayo Clinic (technology originator/collaborator)

Beyond the preview

Go deeper on AtriAN Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtriAN Medical.

Explore the full profile